Company Overview and News

 
Apo Land open to independent investigation of landslide

2018-09-28 bworldonline
APO LAND and Quarry Corp. (ALQC) said on Friday it is allowing geologists and experts to conduct independent investigation of the landslide in Naga, Cebu, a day after Environment Secretary Roy A. Cimatu said the company’s quarry operations will remain suspended.
HLCM HCPHY

 
Cement firm moves coal stockpile after spill

2018-08-03 newsinfo.inquirer.net
DAGUPAN CITY—Cement manufacturer Holcim Philippines Inc. has moved its temporary coal stockpile to enclosed storage areas and put up three additional siltation ponds to prevent a repeat of a coal spill that polluted the shores of Bacnotan town in La Union province.
HLCM HCPHY

1
Holcim net income drops

2018-07-26 bworldonline - 1
EARNINGS of Holcim Philippines, Inc. slumped by a fourth in the second quarter as higher costs and stiff competition dragged the double-digit increase in sales.
HLCM HCPHY

2
Competition, higher costs weigh on Holcim Q2 profit

2018-07-26 bworldonline - 2
Earnings of Holcim Philippines, Inc. slumped by a fourth in the second quarter of 2018, as higher costs and stiff competition dragged the double-digit increase in sales.
HLCM HCPHY

1
Holcim assures cement production ready to meet Mindanao demand

2018-07-12 bworldonline - 1
DAVAO CITY — Holcim Philippines, Inc. is preparing to ramp up cement production in Mindanao as demand continues to increase with private sector projects and the government’s “Build, Build, Build” program.
HLCM HCPHY

 
Holcim allots P2.4B for 2018 capex

2018-05-18 business.inquirer.net
The country’s leading cement-maker Holcim Philippines Inc. has earmarked P2.4 billion for capital outlays this year, mostly to boost production capacity and ride on the local construction boom.
HLCM HCPHY

 
Holcim hoping to ride construction boom, control costs

2018-05-18 bworldonline
HOLCIM Philippines, Inc. has outlined its priorities this year, including plans to seize opportunities brought about by an ongoing construction boom, its new head said.
HLCM HCPHY

 
Holcim earmarks P2.4B to boost cement production

2018-05-18 business.inquirer.net
The country’s leading cement-maker Holcim Philippines Inc. has earmarked P2.4 billion for capital outlays this year, mostly to boost production capacity and ride on the local construction boom.
HLCM HCPHY

5
Weak cement prices drag down Holcim PHL’s profit

2018-05-07 bworldonline
HOLCIM Philippines, Inc. reported a 26.5% drop in its attributable profit for the first three months of 2018, as cement prices weakened amid “intense” competition.
HLCM PSKXF PHSXY PSE HCPHY

 
Holcim profit drops in first quarter

2018-05-07 bworldonline
Holcim Philippines, Inc. reported a 26.5% drop in its attributable profit for the first three months of 2018, although noting that sales volumes have started to recover alongside the pick up in demand. — Arra B. Francia
HLCM HCPHY

 
Holcim introduces PROSOLUTIONS to help partners build better amid construction boom

2018-04-30 bworldonline
Much is expected of the construction sector as the government implements an ambitious plan to invest up to P8 trillion in upgrading infrastructures all over the Philippines by 2022.
HLCM HCPHY

5
Holcim Philippines names new chief executive

2018-04-23 bworldonline
HOLCIM Philippines, Inc. has appointed the former chief of LafargeHolcim’s cement operations in the United States as its new president and chief executive officer.
HLCM PSKXF PHSXY PSE HCPHY

 
Sapna R. Sood: An empowering leadership

2018-03-23 bworldonline
At a young age, Sapna R. Sood, president and chief executive officer of Holcim Philippines, a leading building solutions company, had her sights already set on studying history and working for the United Nations, when a trip to an oil refinery made her think twice.
HLCM HCPHY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...